NATTO: SHARE ISSUE
Based on the power of attorney granted at the annual general meeting of NattoPharma ASA ("NattoPharma" or "Company") on June 25, 2015, the Board of Directors of NattoPharma has in board proceedings July 21st, 2016 approved a share issue of 125 000 new shares, each with a face value of NOK 3 per share.
The share issue will be completed through issuance of new shares to strategic partners, who have over the last two years provided, and will continue to provide, valuable support for the buildup and continued development of NattoPharma. The shares will be issued to the following persons/companies;
| Name | Position / Function | Granted shares | Shares prior to share issue | Shares after share issue |
| Katarzyna Maresz | Strategic Partner | 100.000 | 0 | 100.000 |
| Complementary Medicines Group | Strategic Partner | 25.000 | 0 | 25.000 |
Price to be paid for each share is NOK 3 per share. The share issue is expected to be completed within August 31st, 2016.
As a result, the share capital will be increased by NOK 375 000. After completing the share issue announced 27thJune of NOK 915 000, which is still in progress, and the above mentioned share issue, the Company’s new share capital will be NOK 52 709 799 divided into 17 569 933 shares, each with a face value of NOK 3.
* * *
For more information, please contact:
Frode Bohan, Chairman
E-mail: frode.bohan@nattopharma.com
Kjetil Ramsøy, Chief Financial Officer
E-mail: kjetil.ramsoy@nattopharma.com
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Tags: